Skip navigation
Watchlist Sponsored By :


Current DateTime: 09:59:35 27 Nov 2009
LinksList Documentid: 24355697
  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

  • Wines for the Holidays

      Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES


Current DateTime: 09:59:35 27 Nov 2009
LinksList Documentid: 33793611
  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?


Current DateTime: 09:59:35 27 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Celgene Cancer Drug Trial Temporarily Suspended
By: Reuters | 11 Apr 2007 | 10:53 AM ET
Text Size

A trial of Celgene's [CELG  Loading...      ()   ] cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, or SWOG, which was running the late-stage trial.

The statement, made on the group's Web site, did not give details.

However, Matthew Osborne, an analyst at Lazard Capital Markets, said he believes the suspension is designed to alter the protocol to allow patients to switch to a different treatment regimen, which was recently shown to improve survival.

Brian Gill, a spokesman for Celgene, confirmed that the trial has been temporarily closed but said the company could shed no light on the reason for the suspension.

"Matt Osborne's assumptions are very interesting and could well have validity but we don't have any definitive information," he said.

The SWOG study is testing Revlimid plus standard dose dexamethasone, a steroid, versus dexamethasone alone as a first-line treatment for multiple myeloma.

The news comes on the heels of a recent finding by the Eastern Cooperative Oncology Group, or ECOG, that patients  who took Revlimid plus low-dose dexamethasone had a survival advantage over patients who took Revlimid plus standard dose dexamethasone.

It is not clear whether SWOG plans to stop the trial completely, but Osborne said that with a survival advantage for Revlimid plus low-dose dexamethasone it could be considered unethical to continue patients on standard dose dexamethasone alone.

"What this does is build on the evidence that Revlimid plus low-dose dexamethasone will become the standard of care in frontline multiple myeloma," Osborne said.

Currently, Revlimid is approved by the U.S. Food and Drug Administration in combination with standard-dose dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

Osborne said, however, that as data from the Revlimid plus dexamethasone trials is further disseminated, physicians are likely to increase their use of Revlimid plus low-dose dexamethasone as their first choice therapy, even though it has not formally been approved for such use.

Physicians are allowed to prescribe drugs "off label" but companies are not allowed to market them for unapproved uses.

Revlimid is a successor to Celgene's drug Thalomid, currently the leading treatment for multiple myeloma.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • These four sectors will be the next to lead the market.
  • Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
  • T shirt man
  • From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
  • It may be the most unusual guide to business you'll read.
  • Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
  • "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
ADD COMMENTS
Remaining characters


Current DateTime: 06:14:06 27 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 09:11:31 27 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 10:38:14 27 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 07:56:30 27 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters